Clinical Trial Update: A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating the safety and efficacy of SEP-363856 in adults with major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED